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Abstract
Background: Bone mesenchymal stem cells (MSCs) can promote liver regeneration and inhibit inflammation and
hepatic fibrosis. MSCs also can serve as a vehicle for gene therapy. Smad7 is an essential negative regulatory gene
in the TGF-β1/Smad signalling pathway. Activation of TGF-β1/Smad signalling accelerates liver inflammation and
fibrosis; we therefore hypothesized that MSCs overexpressing the Smad7 gene might be a new cell therapy
approach for treating liver fibrosis via the inhibition of TGF-β1/Smad signalling.
Methods: MSCs were isolated from 6-week-old Wistar rats and transduced with the Smad7 gene using a lentivirus
vector. Liver cirrhosis was induced by subcutaneous injection of carbon tetrachloride (CCl4) for 8 weeks. The rats
with established liver cirrhosis were treated with Smad7-MSCs by direct injection of cells into the main lobes of the
liver. The expression of Smad7, Smad2/3 and fibrosis biomarkers or extracellular matrix proteins and
histopathological change were assessed by quantitative PCR, ELISA and Western blotting and staining.
Results: The mRNA and protein level of Smad7 in the recipient liver and serum were increased after treating with
Smad-MSCs for 7 and 21 days (P < 0.001). The serum levels of collagen I and III and collagenase I and III were
significantly (P < 0.001) reduced after the treatment with Smad7-MSCs. The mRNA levels of TGF-β1, TGFBR1, α-SMA,
TIMP-1, laminin and hyaluronic acid were decreased (P < 0.001), while MMP-1 increased (P < 0.001). The liver fibrosis
score and liver function were significantly alleviated after the cell therapy.
Conclusions: The findings suggest that the MSC therapy with Smad7-MSCs is effective in the treatment of liver
fibrosis in the CCl4-induced liver cirrhosis model. Inhibition of TGF-β1 signalling pathway by enhancement of Smad-
7 expression could be a feasible cell therapy approach to mitigate liver cirrhosis.
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Introduction
Chronic hepatitis B virus (HBV) infection is a global pub-
lic health issue with an estimated prevalence of 3.5% in
2017 with 257 million people living with chronic HBV in-
fection [1]. There are 93 million people infected with HBV
living in China, including 20 million patients with chronic
hepatitis B [2]. Approximately 15–40% of the patients with
chronic hepatitis B will develop liver cirrhosis, and 4–5%
of the patients may progress towards decompensated liver
cirrhosis [3, 4]. The 5-year mortality in patients with com-
pensated liver cirrhosis is 14–20% and with decompen-
sated liver cirrhosis as high as 70–86% [1–3]. Liver
cirrhosis is a major cause of morbidity and mortality glo-
bally and imposes a substantial health burden on many
countries [3]. Currently, there are no treatments available
to specifically target fibrosis and cirrhosis, and liver trans-
plantation is the only curative option for patients with
liver cirrhosis, but unfortunately, there are simply not
enough donated livers to meet the demand for it. There-
fore, research on non-surgical strategies to prevent the de-
velopment of liver cirrhosis is in an urgent need.
Cell therapy is an emerging approach for treating liver cir-
rhosis [5]. Bone marrow mesenchymal stem cells (MSCs) are
multipotent stem cells with low immunogenicity, which can
differentiate into liver cells. MSCs can promote liver regener-
ation and suppress liver fibrosis and thus may partially re-
cover liver function and retard the progression of liver
cirrhosis [6]. This new approach has been considered as po-
tentially the most effective non-surgical treatment for liver
cirrhosis [6, 7]; however, clinical trials using stem cells seem
to not be so successful [5, 8–10]. Therefore, development of
stem cells carrying a specific gene related to the regulation of
fibrosis could be a new direction for cell therapy.
Liver cirrhosis mainly results from excessive depos-
ition of newly generated extracellular matrix (ECM) in
response to injury, which involves the activation of hep-
atic stellate cells (HSCs) [11]. HSCs are a liver-specific
type of pericytes located in the subendothelial layer in
the space of Disse. They are major fibrogenic precursor
cells that transdifferentiate into fibrogenic myofibro-
blasts in the liver. The transdifferentiation from a quies-
cent to a proliferative, migratory and fibrogenic
phenotype (i.e. myofibroblast) is driven by inflammatory
cytokines, which results in a large amount of ECM syn-
thesis and the expression of alpha-smooth muscle actin
(α-SMA). The transforming growth factor (TGF)-β is
the main fibrogenic cytokine in the stimulation of HSC
transdifferentiation [12] and the signalling of epithelial-
to-mesenchymal transitions [13]. Activation of TGF-β1
not only promotes extracellular matrix (ECM) formation
but also inhibits ECM degradation and thus accelerates
the progression of liver fibrosis [12, 14].
SMADs are transducer proteins and signal TGF-β1 acti-
vation to the downstream gene transcription [13, 15].
There are eight SMAD proteins in mammals, six of which
have effector function (Smad1—Smad5 and Smad8 (also
known as Smad9)) and two of which are inhibitory
(Smad6 and Smad7) and mediate the negative feedback of
the TGF-β1/SMAD signalling pathway [15, 16]. Overex-
pression of Smad7 inhibits collagen expression and cell
proliferation of HSCs [14]. Our previous study has also
demonstrated that rat MSCs overexpressing the Smad7
gene were able to inhibit the fibrogenesis of HSCs [17].
To further validate the therapeutic potential of the Smad7
gene, MSCs overexpressing Smad7 will be injected into
rats with liver cirrhosis induced by carbon tetrachloride
(CCl4). This in vivo study on the rat liver cirrhotic model




All animal experiments were performed under the eth-
ical guidelines of the Ethics Committee of The Second
Affiliated Hospital of Jinan University (Shenzhen,
China). Six-week-old Wistar rats of either sex (160–200
g body weight) were purchased from the Guangdong
Medical Science Experiment Center (Guangdong Prov-
ince, China). Rats were maintained under constant con-
ditions of temperature (25 °C), air humidity (50–70%)
and a 12:12-h light dark cycle. All rats had free access to
standard chow and tap water throughout the experi-
ments and were allowed 7–10 days of acclimation to the
room and manipulation prior to the experiments. The
animal work was performed in the Animal Centre at the
North Campus of Sun Yat-sen University.
Experimental cirrhosis model and transplantation of
Smad7-EGFP-MSCs
The CCl4-induced cirrhosis model was chosen in this
study because it is commonly used for liver cirrhosis
study with good reproducibility [18]. Rats were randomly
divided into four groups: (1) rats injected with 0.9%
NaCl as the control group, (2) rats receiving CCl4 to in-
duce liver fibrosis, (3) rats receiving CCl4 plus the injec-
tion of MSCs and (4) rats receiving CCl4 plus the
injection of Smad7-EGFP-MSCs. Rat liver fibrosis was
induced by subcutaneously injecting 40% carbon
tetrachloride-rapeseed oil liquor (5 ml/kg as the initial
dose, followed by 3 ml/kg, 2 times a week for 8 weeks).
Each group contained 20 rats to monitor the patho-
logical and biomarker changes at different time points.
For the transplantation of MSCs or Smad7-EGFP-
MSCs, rats were anesthetized by intraperitoneal injection
of 3% pentobarbital sodium (70 mg/kg) before making
an upper midline abdominal incision to locate the liver.
The MSCs or Smad7-EGFP-MSCs were delivered into
the liver by direct injection via the surgical incision, and
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3–5 × 106 of Smad7-EGFP-MSCs or MSCs at a volume
of 0.4 ml were injected into the liver of each animal in the
cell treated groups (~ 0.1ml each for injection into 3–4
liver lobes), and 0.4ml phosphate-buffered saline (PBS)
was injected in the control groups. The incision was su-
tured after injections, and all the animals were recovered
after surgery. The experimental procedures were approved
by the Ethics Committee of Shenzhen People’s Hospital.
Isolation, purification and characterization of MSCs
Six-week-old male Wistar rats were sacrificed, and their fe-
murs were dissected out. MSCs were isolated and purified
from the bone marrow using density gradient centrifugation
and the marrow adherence method as described previously
[17, 19, 20]. Briefly, bone marrow cells were harvested by
carefully washing the marrow cavity with PBS. The cells were
centrifuged at 400 g for 10min, resuspended in the culture
medium using a 21-gauge syringe and filtered using a 70-μm
nylon mesh filter. The nucleated cells were isolated by dens-
ity gradient centrifugation with Ficoll/Paque (Amersham
Pharmacia). The non-adherent cells were discarded after cell
culture for 48 h. The MSCs were cultured in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 medium (Thermo
Fisher Scientific, Waltham, MA, USA) supplemented with
10% foetal bovine serum (FBS) at a density of 1 × 106 cells/
ml. The culture medium was replaced every 3 days. Cells
were passaged using 0.05% trypsin-EDTA when 80% conflu-
ence was reached. The MSC cell markers were characterized
at passage 3 using FACS, including CD31, CD34, CD45,
CD73, CD105 and CD106.
Construction of rat Smad7-EGFP-MSCs
The Entry/Gateway® system was employed to construct
the lentiviral vectors that expressed enhanced green
fluorescent protein (EGFP)-tagged Smad7 protein. The
procedure is similar to our previous report [17]. Briefly,
total RNA was extracted from rat cerebral cortex, and
the full sequence of Smad7 was obtained by RT-PCR
with 100% identity to the GenBank accession No.
AH008243.2. Upon cleaving the lentiviral vector, pCDH-
CMV-MCS-EF1-copEGFP (Shanghai GenePharma Co.,
Ltd., Shanghai, China) with restriction enzymes EcoRI
and BamHI (Shanghai GenePharma Co., Ltd.), the
Smad7 cDNA tagged with EGFP was inserted into the
vector. The rat MSCs at passage 3 were then infected
with the lentiviral vector, and the efficiency of induction
was evaluated under a fluorescence microscope. The
MSCs with stable expression of Smad7-EGFP were sub-
cultured for the experiments of liver injection, and
MSCs at the same passage number were used as control.
Histology and fibrosis quantification
The valuation of liver cirrhosis was exclusively based on
histological criteria with characteristics of architectural
distortion and the formation of regenerative nodules of
hepatocytes surrounded by fibrous tissue. After injection
with CCl4 for 4 and 8 weeks, rats from the control group
and the CCl4-treated group were sacrificed and the hist-
ology of liver cirrhosis was examined using paraffin-
embedded sections. Briefly, portions of the left lateral
and the median lobes of the liver were placed in 10%
neutral buffered formalin and processed for paraffin em-
bedding. Tissue sections were cut at 6-μm thickness
using a microtome and stained with haematoxylin-eosin,
Sirius red (Direct Red 80, Sigma-Aldrich) or Masson
Trichrome (Bio-Optica Milano SpA). The staining was
assessed by a trained pathologist in a blinded way to the
groups for the diagnosis of cirrhosis and fibrosis quantifica-
tion. The degree of liver fibrosis was categorized into five
groups according to the following scoring system [21, 22]: 0,
no fibrosis, normal liver and absence of fibrosis; I, fibrosis
present (collagen fibres present that extend from the portal
triad or central vein to the peripheral region); II, mild fibrosis
(mild collagen fibres present with extension without com-
partment formation); III, moderate fibrosis (moderate colla-
gen fibres present with a certain level of pseudo-lobe
formation); and IV, severe fibrosis (severe collagen fibres
present with thickening of the partial compartments and fre-
quent pseudo-lobe formation).
Liver function test
Serum was collected at day 21 after cell transplantation.
The alanine transaminase (ALT), aspartate transaminase
(AST), albumin and total protein were analysed using a
semi-automatic biochemical analyser (BT-815A, Shang-
hai Sanco Instrument Co. Ltd., China).
Quantitative real-time RT-PCR
Total RNA samples were extracted using Trizol (Invitro-
gen, CA, USA) according to the manufacturer’s instruc-
tions. Real-time quantitative PCR analysis was performed
using Applied Biosystems 7500 Real-Time PCR Systems
(Applied Biosystems, Foster City, CA). The housekeeping
gene GAPDH was used as an internal control for relative
quantification. The mRNAs of Smad2, Smad3, Smad7,
TGF-β1, TGFBR1, TIMP-1, MMP1, collagen I, collagen III
and α-SMA were quantified using the SYBR green method
after cell transplantation for 7 and 21 days. The real-time
PCR procedure and the calculation of relative quantifica-
tion were similar to our previous reports [23, 24]. The pri-
mer sets used in this study were purchased from
Invitrogen (Supplementary Table 1).
Western blotting and ELISA detection
The Western blotting procedure is similar to our previ-
ous reports [17, 23]. Briefly, the liver tissue from the rat
model was lysed in RIPA buffer containing a proteinase
inhibitor cocktail (Biocolor BioScience & Technology,
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Shanghai, China). The protein concentration was deter-
mined using bicinchoninic acid (Bioss, Beijing, China).
Protein was loaded at 30 μg/gel each lane, separated on
10% SDS-PAGE and transferred to nitrocellulose
membranes. The blots were incubated with rabbit pri-
mary antibodies anti-MMP-1 (1:1000, sc-241561) or
TIMP-1 (1:1000, sc-5538) (Santa Cruz Biotech, USA)
and anti-GAPDH (rabbit monoclonal antibody, 1:1000,
Ab181602, Abcam, UK) at 4 °C overnight, then washed
extensively with 0.1% Tween-20 in PBS and incubated
with a secondary antibody conjugated to horseradish
peroxidase (1:5000; sc-2004, Santa Cruz, USA) at room
temperature for 3 h. The blot was visualized using the
ECL system (Amersham, UK).
The serum levels of Smad7, collagen I, collagen III,
laminin and hyaluronic acid were detected using ELISA
according to the manufacturer’s instruction. The ELISA
kits for Smad7 (# CSB-E09225r) and hyaluronic acid (#
CSB-E08120r) were purchased from CUSABIO Technol-
ogy LLC (Wuhan, China), and the kits for collagenase I
(# CX20064), collagenase III (# kt210320) and laminin (#
KT20202) were from MSKBIO (Wuhan, China).
Statistics
Data are expressed as mean ± standard deviation (SD).
One-way analysis of variance (ANOVA) was used to
compare the means from more than three groups, and
unpaired t test was used for two group comparison. A
value of P < 0.05 was considered a significant difference.
Results
MSC primary culture and transduction efficiency with the
lentivirus vector
The isolated bone marrow MSCs expanded extensively
in the culture medium from single cell-derived colonies
in ~ 2 weeks under optimal conditions. Morphological
examples of isolated MSCs from passage 1 were shown
(Supplementary Fig. 1A). The phenotypes of MSCs were
characterized by positive and negative cell markers
(CD31, CD34, CD45, CD73, CD105 and CD106) using a
flow cytometer as we reported previously [17]. After
obtaining enriched MSCs, the cells were transduced with
the lentivirus vector carrying the EGFP-Smad7 gene.
The condition of transduction was optimized by using
different MOIs in the range 5–80, and the transduction
efficiency was assessed using fluorescence microscopy.
The protein expression of EGFP-Smad7 was evident
after the removal of the virus supernatant and more than
95% of cells were positive at day 3 or even higher at day
5 (Supplementary Fig. 1B). The MSCs overexpressing
Smad7 at passage 3 were used for in vivo cell therapy in
the following liver cirrhosis model.
Fig. 1 CCl4-induced liver fibrosis assessed by Masson’s trichrome staining (× 400). a Normal rat liver tissue as control. b Rat liver tissue obtained at
4 weeks after injection of CCl4 (prior to cirrhosis). c Typical liver cirrhosis tissue section after injection of CCl4 for 8 weeks. d Histological scores for
liver fibrosis (n = 5 for each group). ***P < 0.001 comparing with the control group
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Establishment of the rat liver cirrhosis model
Rat liver cirrhosis was induced by subcutaneously inject-
ing 40% carbon tetrachloride (CCl4) in rapeseed oil. The
liver fibrosis was evaluated by Masson’s trichrome stain-
ing. In normal rat liver tissue sections, the structure of
the hepatic lobule was clear and there was no evident
collagen fibres present or very few fibres extended from
the portal triad or central vein to the peripheral region
of the hepatic cords (Fig. 1a). After injection of CCl4 for
4 weeks, hepatocellular fatty degeneration and hepatic
cell necrosis accompanied with obvious inflammation
were present. The increased collagen staining with evi-
dent fibres extended from the central vein to the periph-
eral region, which represented the stage prior to
cirrhosis (Fig. 1b). After injection of CCl4 for 8 weeks,
the liver cirrhosis was evident, which was characterized
by disordered architecture of hepatic cords and lobule
structure, fibrous tissue and hyperplasia, collagen pro-
duction, and a large number of inflammatory cells infil-
trated in the portal area and surrounding central veins
(Fig. 1c). The mean scores of liver fibrosis for normal
liver tissue and liver tissues obtained at early (4 weeks)
and late (8 weeks) stages of the CCl4-induced cirrhosis
were 0, 1.45 and 3.35, respectively (Fig. 1d), suggesting
the successful induction of rat liver cirrhosis after injec-
tion of CCl4.
Enhanced expression of Smads7 after Smad7-MSC
therapy
In order to confirm if the Smad7-EGFP-MSCs were suc-
cessfully transplanted into the liver, one rat from each
group was sacrificed at 24 h, 1 week and 4 weeks after
cell transplantation and the livers were dissected out for
frozen sectioning. The distribution of Smad7-EGFP-
Fig. 2 Distribution of Smad7-EGFP-MSCs in the liver and the expression of Smads. a Example of direct injection of Smad7-EGFP-MSCs into the
liver lobes. The distribution of Smad7-EGFP-MSCs (green fluorescence) in the liver tissue was detected on the frozen sections using a laser
confocal microscope at the time points of 24 h, 7 days and 21 days after cell injection. b Smad7 mRNA quantification in the groups of control
(vehicle control without CCl4), cirrhosis group (with CCl4 injection), cirrhosis group treated with MSCs and cirrhosis group treated with Smad7-
MSCs. c Serum protein level of Smad7 detected using ELISA (n = 4). d Smad2 mRNA quantification using real-time PCR. GAPDH was set as
housekeeping gene control for relative quantification (n = 6). e Smad3 mRNA quantification (n = 6). **P < 0.01 or ***P < 0.001 comparing with the
control group; ###P < 0.001 comparing with the cirrhosis group
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MSCs was examined under a confocal microscope, and
MSCs with green fluorescence were diffused at the por-
tal area after 24-h cell transplantation. After cell trans-
plantation for 7 days, the cells with green fluorescence
were migrated and appeared in the necrotic area of the
liver, and after 21 days of transplantation, the Smad7-
MSCs were more sparsely distributed in the liver
(Fig. 2a). This suggested that the transplanted Smad7-
EGFP-MSCs can survive in the liver and migrate in the
live lobules.
The expression of Smad7 in the liver tissue was de-
tected by real-time PCR. The Smad7 mRNA was de-
creased in the CCl4-induced liver cirrhosis group. After
treatment with Smad7-MSCs, the expression of Smad7
was significantly increased in the recipient liver with cir-
rhosis. Smad7 was also increased in the group treated
with MSCs alone compared to the control. The en-
hanced expression of Smad7 was more robust after the
cell transplantation for 21 days (Fig. 2b). The serum level
of Smad7 protein was also determined using ELISA, and
the Smad7 was significantly increased after transplant-
ation of Smad7-MSCs or MSCs. The Smad7 levels for
the group treated with Smad7-MSCs were much higher
than those for the other groups (Fig. 2c).
Smad2 and Smad3 as effectors of TGF-β signalling
were also detected in the liver tissue using real-time
PCR. The enhanced expression of Smad2 and Smad3
was observed after the induction of liver cirrhosis. After
cell transplantation, the expression levels of both Smad2
and Smad3 were decreased (Fig. 2d, e), suggesting that
enhanced Smad7 activity after cell therapy may affect
other SMAD isoform expression.
Fig. 3 Detection of fibrosis biomarkers collagen and collagenase. a Real-time PCR detection of collagen I and collagen III expression in the liver
tissues treated with Smad7-MSCs, comparing with the control (vehicle), cirrhosis group (with CCl4 injection) and the cirrhosis group treated with
MSCs (n = 6 for each group). b Quantification of collagen III mRNA (n = 6 for each group). c ELISA detection of collagenase 1 and collagenase III
(d) in rat serum (n = 4 for each group). *P < 0.05 or ***P < 0.001 comparing with the control group; ##P < 0.01 or ###P < 0.001 comparing with the
cirrhosis group
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Effects on fibrosis biomarkers
The mRNAs of collagen I and III were detected using real-
time PCR. After induction of liver cirrhosis with CCl4 injec-
tion, the collagen I and III were significantly increased in
comparison to the control group. After transplantation with
MSCs, the enhanced expression of collagen mRNAs was re-
duced, and the reduction in the group treated with Smad7-
MSCs for 21 days was much more significant (Fig. 3a, b).
The serum collagenase I and III were detected using
ELISA. The peripheral blood was collected, and the
serum was isolated from the rats after MSC transplant-
ation for 7 days and 21 days. The levels of collagenase I
and III were significantly increased in the CCl4-induced
liver cirrhosis group. Treatment with Smad7-MSCs sig-
nificantly reduced the level of collagenases (Fig. 3c, d),
suggesting that the cell therapy with Smad7-MSCs is ef-
fective in the prevention of liver fibrosis.
Effects on TGF-β1, TGFBR1 and α-SMA
The mRNAs of TGF-β1, TGFBR1 and α-SMA were
quantified using real-time PCR. Induction of liver cir-
rhosis with CCl4 significantly increased the expression of
TGF-β1 and α-SMA; however, TGFBR1 expression was
not significantly changed. After transplantation of
Smad7-MSCs, the expression of TGF-β1 and TGFBR1
(Fig. 4a, b) was decreased, suggesting the potential allevi-
ation of TGF-β1 signalling activity after Smad-7 cell
therapy. The α-SMA is a biomarker of myofibroblasts
and also acts as an indicator of HSC activation, which
precedes fibrous tissue deposition in the liver [25]. The
expression of α-SMA was increased in the CCl4-induced
liver cirrhosis group; however, the expression was sig-
nificantly decreased in the group receiving Smad7-MSCs
(Fig. 4c), suggesting less activity of HSCs occurred in the
liver after cell therapy.
Effects on laminin, hyaluronic acid, MMP-1 and TIMP-1
The serum level of laminin and hyaluronic acid was measured
using ELISA after MSC transplantation for 7 days and 21 days.
The serum levels of laminin and hyaluronic acid were signifi-
cantly increased in the CCl4-induced liver cirrhosis group.
Treatment with Smad7-MSCs reduced the serum levels of the
two proteins (Fig. 5a, b), suggesting that the cell therapy with
Smad7-MSCs can change the extracellular matrix proteins.
MMP-1 is a member of the MMP family, which is re-
sponsible for the type I and type III collagen degradation
in ECM. TIMP-1 is an active polypeptide that can in-
hibit the function of MMP-1 by forming a reversible co-
valent complex with MMP-1. The levels of TIMP-1 were
positively correlated with the level of liver inflammation
and fibrosis, and the levels of MMP-1 were negatively
correlated with the level of fibrosis [26]. Our data
showed that the mRNA and protein levels of TIMP-1
were remarkedly increased and the levels of MMP-1
were significantly decreased in the CCl4-induced cirrho-
sis liver group. After treatment with Smad7-MSCs for
21 days, TIMP-1 was decreased, while MMP-1 was
increased (Fig. 5c–e). These results suggested that the al-
leviation of liver fibrosis after treatment with Smad7-
MSCs could be mediated by the alternation of TIMP-1
and MMP-1 expression.
Liver fibrosis and liver function improved by Smad7-MSC-
base gene therapy
In the PBS-treated liver cirrhosis group, the liver fibrosis
score achieved 3.6 after initial injection of CCl4 for 11
Fig. 4 Downregulation of TGF-β1, TGFBR1 and α-SMA after Smad7-MSC treatment. Real-time PCR detection of TGF-β1 (a), TGFBR1 (b) and α-SMA
(c) expression in the rat liver tissues treated with Smad7-MSCs, comparing with the control (vehicle), cirrhosis group (with CCl4 injection) and the
cirrhosis group treated with MSCs (n = 6 for each group). The GAPDH was set as the housekeeping gene for relative quantification (n = 6 for each
group). **P < 0.01 or ***P < 0.001 comparing with the control group; ###P < 0.001 comparing with the cirrhosis group
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weeks (8-week liver cirrhosis induction + 21-day treat-
ment) and significantly higher than the control group
without injection of CCl4 (3.6 ± 0.24 vs 0.5 ± 0.22, n = 5).
Transplantation of MSCs showed a tendency of fibrosis
reduction, but did not achieve a statistical difference.
However, the group treated with Smad7-MSCs for 21
days significantly reduced histopathological fibrosis
scores (Fig. 6), suggesting that Smad7-MSC-base gene
therapy can reduce liver fibrosis. The activity of ALT,
AST, albumin and total protein were determined after
the treatment with Smad7-MSCs for 21 days (Table 1).
The ALT and AST were significantly reduced while the
total protein level increased comparing with the CCl4-
treated group, suggesting that the liver function was
alleviated.
Discussion
In this study, we have shown that MSCs overexpressing
the Smad7 gene can exert therapeutic effects via the
reduction of fibrosis biomarkers (collagen and collage-
nase activity) and inflammatory markers (TGF-β1 and
TGFBR1). The extracellular matrix biomarkers, histo-
pathological score for liver fibrosis, and liver function
were improved after MSC-Smad7 cell therapy. Our find-
ings provide a direct in vivo evidence that Smad7-MSC
therapy is effective in the treatment of CCl4-induced
liver cirrhosis.
To restore liver functionality in patients with liver cirrho-
sis, cell therapy strategies using bone marrow-derived stem
cells [6, 27] or MSCs carrying specific genes are sought-
after research areas [5, 9]. The treatment with MSCs alone
showed some degree of alleviation of liver fibrosis and also
inhibited HSC proliferation, which is in accordance with
the studies in mouse or rat models [10, 28, 29]. Here we
have firstly validated the effectiveness of cell therapy using
MSCs overexpressing the Smad7 gene on the CCl4-induced
in vivo animal model. As we expected, the therapeutic ef-
fect was more significant in the group treated with Smad7-
Fig. 5 Changes in extracellular matrix protein laminin, hyaluronic acid, TIMP-1 and MMP-1. ELISA detection of laminin (a) and hyaluronic acid (b)
in the sera from the rats treated with Smad7-MSCs for 7 and 21 days in comparison with the control group (vehicle), cirrhosis group (with CCl4
injection) and the cirrhosis group treated with MSCs (n = 4 for each group). c, d Quantitative PCR for TIMP1 and MMP-1. GAPDH was used as the
housekeeping gene for relative quantification (n = 6 for each group). e TIMP-1 and MMP-1 detected by Western blotting in the liver lysate (n = 5
for each group). *P < 0.05, **P < 0.01 or ***P < 0.001 comparing with the control group; ###P < 0.001 comparing with the cirrhosis group
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MSCs comparing with the group treated with MSCs alone,
suggesting that MSCs overexpressing Smad7 are more effect-
ive in the treatment of liver cirrhosis via inhibiting TGF-β1-
Smad signalling pathway. The expression of Smad2 and
Smad3 was also examined in the study; both enhanced ex-
pression of Smad2 and Smad3 in the CCl4-induced liver cir-
rhosis rats was decreased after injection with Smad7-MSC or
MSCs, suggesting that MSC therapy may affect other gene
expression as well and thus exert overall protective effects.
The MSCs isolated from the bone marrow are
characterized by physical, morphological, phenotypical
and functional properties [30]. The expression of cell
markers has been confirmed as previously described
[17, 19]. MSCs at passage 3 were used for cell therapy
to avoid potential phenotype change. The migration of
Smad7-EGFP-MSCs in the liver was examined after dir-
ect injection into different lobes via the detection of the
fluorescent report protein, EGFP. The underlying
mechanisms for MSCs in the treatment of liver cirrho-
sis are still unclear [31]. The explanations could be as
follows: (1) MSCs may proliferate and differentiate into
liver cells in the liver microenvironment. The enhanced
levels of Smad7 in the liver and in the serum suggest
the possibility of cell number expansion in the body
after cell transplantation. (2) MSCs have been shown
anti-inflammatory and thus can reduce the activation of
HSCs [32]. The decreased expression of inflammatory
biomarkers was also observed in this study after Smad7-
MSC or MSC treatment. (3) MSCs have been recently re-
ported to affect macrophage function, which will affect
immune response and tissue repair in the damaged liver,
(4) MSCs change matrix metalloproteinases to reduce the
ECM. Our results on MMP1 and TIMP1 support this hy-
pothesis. (5) The paracrine/endocrine mechanisms may
exist via the up- or downregulation of inflammatory fac-
tors or cytokines after receiving MSCs [33]. (6) The exo-
some of MSCs and cell culture media only seem to have
an effect, suggesting that the mechanism is not due to the
cell itself, but due to the secretion or humoral factors re-
leased from the cells [9].
Fig. 6 Histopathological evaluation of liver fibrosis after Smad7-MSC therapy. a The rat liver tissue sections were stained using Masson’s trichrome
stain method and assessed by fibrosis semi-quantitative scoring method (grades 0–5). The isolated collagen fibres (indicated by arrow) and
collagen around the wall of central vein (V) were stained blue. Examples for the control group (vehicle), cirrhosis group (with CCl4 injection) and
the cirrhosis groups treated with MSCs or Smad7-MSCs for 21 days. b Mean ± SD for the scoring on severity of fibrosis (n = 5 for each group)
Table 1 Liver function tests for the groups treated with or without CCl4 or MSC-Smad7 for 21 days
Group Number ALT(U/L) AST(U/L) ALB (g/dl) TP (g/dl)
Control 6 26.8 ± 9.2 66.9 ± 7.8 43.7 ± 9.1 70.7 ± 7.4
CCl4-treated 6 128.6 ± 10.3*** 138.4 + 6.1*** 23.4 ± 8.6** 43.8 + 6.4***
CCl4+MSC 6 119.6 ± 10.1*** 135.7 ± 6.8*** 22.8 ± 8.1** 44.9 ± 6.3***
CCl4+MSC-Smad7 6 65.3 ± 11.9*
, ### 82.9 ± 7.7**,### 31.7 ± 7.1* 63.6 ± 5.3###
ALT alanine transaminase, AST aspartate transaminase, ALB albumin, TP total protein. *P < 0.05, **P < 0.01 and ***P < 0.001 comparing with the control group. #P <
0.05, ##P < 0.01 and ###P < 0.001 comparing with the CCl4-treated group
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Due to the high cost, scarce source of donors and
other limitations, liver transplantation is still very limited
in clinical practice, and artificial liver support systems
can only temporarily replace and assist liver function,
but they are unable to reduce the mortality of patients
with liver cirrhosis. Stem cells have low immunogenicity
and high potency for proliferation and differentiation,
which may play a key role in the treatment of liver cir-
rhosis. Organ injection of MSCs is a feasible approach in
clinical settings. The MSCs which overexpress a specific
gene, such as Smad7 in this study, may achieve max-
imum clinical efficacy via targeting specific signalling
pathways, which may shed a light on future therapeutics
for end-stage liver disease. In addition, targeting TGF-
β1-Smad7 signalling is applicable to the fibrosis of other
organs, such as lung fibrosis [34], and thus, MSC-Smad7
cell therapy should open a new strategy for anti-fibrosis
therapy.
Conclusions
In this study, MSC-Smad7 cells were transplanted into
the liver of rats with CCl4-induced liver cirrhosis and
the inflammatory and fibrosis biomarkers in serum and
liver tissue were determined. The liver fibrosis bio-
markers and histology score were significantly mitigated
after stem cell transplantation. The findings from this
in vivo rat model provide the first direct in vivo evidence
to suggest that the MSC-Smad7 cell therapy is an effect-
ive approach to prevent liver cirrhosis development,
which is of clinical significance for future therapeutic
development.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13287-020-01911-4.
Additional file 1: Supplementary Fig. 1. Example of cultured bone
marrow MSCs and the expression of Smad7-EGFP. (A) Example of MSCs
isolated from rat bone marrow and cultured at passage 1. (B) MSCs in-
fected with a lentiviral vector carrying Smad7-EGFP gene. Supplemen-
tary Fig. 2. Examples of western blotting. The cropped box areas are
presented in Fig. 5. Lane 1: Cirrhosis+MSC-Smad7 (21 day); Lane 2: Cirrho-
sis+BMSCs (21 day); Lane 3 Cirrhosis (21 day); Lane 4: Conrol (21 day); Lane
5: Cirrhosis+MSC-Smad7 (7 day); Lane 6: Cirrhosis+BMSCs (7 day); Lane 7:
Cirrhosis (7 day); Lane 8: Control (7 day). Supplementary Table 1. Primer
sequences for RT-PCR.
Abbreviations
α-SMA: Alpha-smooth muscle actin; ALT: Alanine transaminase;
AST: Aspartate transaminase; CCl4: Carbon tetrachloride; ECM: Extracellular
matrix; HBV: Hepatitis B virus; HSCs: Hepatic stellate cells; MMP-1: Matrix
metalloproteinase 1; MSCs: Mesenchymal stem cells; Smad7: Mothers against
decapentaplegic homolog 7; TGF-β1: Transforming growth factor-β1;





D.S. performed and coordinated the experimental work, proposed ideas for
experiments and contributed data analysis and draft manuscript. S.W.
conceived the project and designed the experiments. S.X. supervised the
data analysis, interpreted the data and wrote the manuscript. All authors
read, commented and approved the manuscript.
Funding
This work was supported by the Shenzhen Municipal Science and
Technology Innovation Committee Project (No. JCYJ 20140416122812003).
Availability of data and materials
All data generated and/or analysed during this study are included in this
published article. Data sharing is not applicable to this article as no datasets
were generated or analysed during the current study. However, the data that
support the findings of this study are available from the corresponding
author upon reasonable request.
Ethics approval and consent to participate
Rats were used under the ethical approval and the ethical guidelines of the




The authors declare no conflict of interest.
Received: 11 June 2020 Revised: 17 August 2020
Accepted: 27 August 2020
References
1. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection.
Lancet. 2018;392(10161):2313–24.
2. Liu J, Zhang S, Wang Q, Shen H, Zhang M, Zhang Y, Yan D, Liu M.
Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49
years in rural China: a population-based, cross-sectional study. Lancet Infect
Dis. 2016;16(1):80–6.
3. Collaborators GBDC: The global, regional, and national burden of cirrhosis by
cause in 195 countries and territories, 1990–2017: a systematic analysis for the
Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):
245–66.
4. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a
review. JAMA. 2018;319(17):1802–13.
5. Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J, Corbett C,
Townsend S, Thomas J, Guo K, et al. Granulocyte colony-stimulating factor
and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTI
C): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol
Hepatol. 2018;3(1):25–36.
6. Zhao L, Chen S, Shi X, Cao H, Li L. A pooled analysis of mesenchymal stem
cell-based therapy for liver disease. Stem Cell Res Ther. 2018;9(1):72.
7. Zhang Y, Li Y, Zhang L, Li J, Zhu C. Mesenchymal stem cells: potential application
for the treatment of hepatic cirrhosis. Stem Cell Res Ther. 2018;9(1):59.
8. Lanthier N. Haemopoietic stem cell therapy in cirrhosis: the end of the
story? Lancet Gastroenterol Hepatol. 2018;3(1):3–5.
9. Terai S, Tsuchiya A. Status of and candidates for cell therapy in liver
cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis. J
Gastroenterol. 2017;52(2):129–40.
10. Zhang L, Zhou D, Li J, Yan X, Zhu J, Xiao P, Chen T, Xie X. Effects of bone
marrow-derived mesenchymal stem cells on hypoxia and the transforming
growth factor beta 1 (TGFbeta-1) and SMADs pathway in a mouse model of
cirrhosis. Med Sci Monit. 2019;25:7182–90.
11. El Agha E, Kramann R, Schneider RK, Li X, Seeger W, Humphreys BD, Bellusci S.
Mesenchymal stem cells in fibrotic disease. Cell Stem Cell. 2017;21(2):166–77.
12. Bissell DM, Roulot D, George J. Transforming growth factor beta and the
liver. Hepatology. 2001;34(5):859–67.
13. Su J, Morgani SM, David CJ, Wang Q, Er EE, Huang YH, Basnet H, Zou Y, Shu
W, Soni RK, et al. TGF-beta orchestrates fibrogenic and developmental EMTs
via the RAS effector RREB1. Nature. 2020;577(7791):566–71.
Su et al. Stem Cell Research & Therapy          (2020) 11:395 Page 10 of 11
14. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, Ten
Dijke P, Gressner AM. Smad7 prevents activation of hepatic stellate cells and
liver fibrosis in rats. Gastroenterology. 2003;125(1):178–91.
15. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;
13(10):616–30.
16. David CJ, Massague J. Contextual determinants of TGFbeta action in
development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419–35.
17. Wu SP, Yang Z, Li FR, Liu XD, Chen HT, Su DN. Smad7-overexpressing rat
BMSCs inhibit the fibrosis of hepatic stellate cells by regulating the TGF-
beta1/Smad signaling pathway. Exp Ther Med. 2017;14(3):2568–76.
18. Fortea JI, Fernandez-Mena C, Puerto M, Ripoll C, Almagro J, Banares J, Bellon
JM, Banares R, Vaquero J. Comparison of two protocols of carbon
tetrachloride-induced cirrhosis in rats - improving yield and reproducibility.
Sci Rep. 2018;8(1):9163.
19. Xu J, Qu J, Cao L, Sai Y, Chen C, He L, Yu L. Mesenchymal stem cell-based
angiopoietin-1 gene therapy for acute lung injury induced by
lipopolysaccharide in mice. J Pathol. 2008;214(4):472–81.
20. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem
cells from bone marrow (MSCs) isolated from different strains of inbred
mice vary in surface epitopes, rates of proliferation, and differentiation
potential. Blood. 2004;103(5):1662–8.
21. Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, Qiu DK, Cao AP, Ye J, Cai X,
et al. Grading and staging of hepatic fibrosis, and its relationship with
noninvasive diagnostic parameters. World J Gastroenterol. 2003;9(11):2574–8.
22. Goodman ZD. Grading and staging systems for inflammation and fibrosis in
chronic liver diseases. J Hepatol. 2007;47(4):598–607.
23. Zeng B, Chen GL, Garcia-Vaz E, Bhandari S, Daskoulidou N, Berglund LM,
Jiang H, Hallett T, Zhou LP, Huang L, et al. ORAI channels are critical for
receptor-mediated endocytosis of albumin. Nat Commun. 2017;8(1):1920.
24. Daskoulidou N, Zeng B, Berglund LM, Jiang H, Chen GL, Kotova O, Bhandari
S, Ayoola J, Griffin S, Atkin SL, et al. High glucose enhances store-operated
calcium entry by upregulating ORAI/STIM via calcineurin-NFAT signalling. J
Mol Med (Berl). 2015;93(5):511–21.
25. Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M,
Gentili F, Onetti Muda A, Berloco P, Rossi M, et al. Alpha-SMA expression in
hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis
and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis.
2005;37(5):349–56.
26. Grunwald B, Schoeps B, Kruger A. Recognizing the molecular multifunctionality
and interactome of TIMP-1. Trends Cell Biol. 2019;29(1):6–19.
27. Moore JK, Stutchfield BM, Forbes SJ. Systematic review: the effects of
autologous stem cell therapy for patients with liver disease. Aliment
Pharmacol Ther. 2014;39(7):673–85.
28. Zhang LT, Fang XQ, Chen QF, Chen H, Xiao P, Peng XB, Zhang SX, Li JF,
Mao XR. Bone marrow-derived mesenchymal stem cells inhibit the
proliferation of hepatic stellate cells by inhibiting the transforming growth
factor beta pathway. Mol Med Rep. 2015;12(5):7227–32.
29. Wang ZC, Yang S, Huang JJ, Chen SL, Li QQ, Li Y. Effect of bone marrow
mesenchymal stem cells on the Smad expression of hepatic fibrosis rats.
Asian Pac J Trop Med. 2014;7(4):321–4.
30. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining
multipotent mesenchymal stromal cells. The International Society for
Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.
31. Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, Terai S.
Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells”
for improvement of liver fibrosis and regeneration. Inflamm Regen. 2019;39:18.
32. An SY, Jang YJ, Lim HJ, Han J, Lee J, Lee G, Park JY, Park SY, Kim JH, Do BR,
et al. Milk fat globule-EGF factor 8, secreted by mesenchymal stem cells,
protects against liver fibrosis in mice. Gastroenterology. 2017;152(5):1174–86.
33. Qin ZH, Xu JF, Qu JM, Zhang J, Sai Y, Chen CM, Wu L, Yu L. Intrapleural
delivery of MSCs attenuates acute lung injury by paracrine/endocrine
mechanism. J Cell Mol Med. 2012;16(11):2745–53.
34. Wang C, Gu S, Cao H, Li Z, Xiang Z, Hu K, Han X. miR-877-3p targets Smad7
and is associated with myofibroblast differentiation and bleomycin-induced
lung fibrosis. Sci Rep. 2016;6:30122.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Su et al. Stem Cell Research & Therapy          (2020) 11:395 Page 11 of 11
